Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome

Inclusion Criteria: * Male or female of any race and ≥ 18 years of age. * Willing and able to provide voluntary written informed consent. * Primary or secondary Sjögren's syndrome according to the American- European Consensus Classification Criteria (2002). * Females of childbearing potential must agree to use effective contraception consistently throughout the study (such as hormonal contraception or two forms of barrier contraception) and have a negative urine pregnancy test at screening. * Willing and able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: * Subject has concurrent, uncontrolled medical condition, or psychiatric illness which could place him/her at unacceptable risk. * Subjects with pterygium. * Subjects with active, allergic keratoconjunctivitis, or conjunctivitis of infectious origin. * Subjects with blepharitis requiring treatment. * Subjects with a history of surgery affecting the eye surface, as well as eye injuries within 3 months of screening. * Subjects currently using any topical ophthalmic treatment (including medications for glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs, and cannot discontinue these medications for the duration of the trial. * Female subjects who are pregnant or breast-feeding, or plan to become pregnant during the study. * Subjects that have started or changed the dose of chronic systemic medication within 7 days of Visit 1. * Known hypersensitivity to sodium hyaluronate or any LO2A excipients (glycerol and Carbomer 981) or any of the components in Systane Ultra UD. * Active abuse of alcohol or drugs. * Any condition, which in the opinion of the Investigator, would place the patient at an unacceptable risk if participating in the study protocol.